MRKMerck Sharp & Dohme LLCFinished
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Non-Muscle Invasive Bladder Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 35 (final count)
- Started
- Dec 20, 2024
- Main results expected
- Sep 30, 2026
- Fully finished
- Sep 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Dose Limiting Toxicity (DLT)
Measured over: Up to approximately 7 weeks
Number of Participants Experiencing an Adverse Event (AE)
Measured over: Up to approximately 10 weeks
Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE)
Measured over: Up to approximately 6 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06637423 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC